Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma

Mucinous ovarian carcinoma (MOC) is a unique form of ovarian cancer. MOC typically presents at early stage but demonstrates intrinsic chemoresistance; treatment of advanced-stage and relapsed disease is therefore challenging. We harness a large retrospective MOC cohort to identify factors associated...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Robert L. Hollis, Lorna J. Stillie, Samantha Hopkins, Clare Bartos, Michael Churchman, Tzyvia Rye, Fiona Nussey, Scott Fegan, Rachel Nirsimloo, Gareth J. Inman, C. Simon Herrington, Charlie Gourley
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	ovarian cancer mucinous survival prognosis relapse Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c8786c50a23247a98138b2bae9b70e26
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c8786c50a23247a98138b2bae9b70e26
record_format	dspace
spelling	oai:doaj.org-article:c8786c50a23247a98138b2bae9b70e262021-11-25T17:04:36ZClinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma10.3390/cancers132258392072-6694https://doaj.org/article/c8786c50a23247a98138b2bae9b70e262021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5839https://doaj.org/toc/2072-6694Mucinous ovarian carcinoma (MOC) is a unique form of ovarian cancer. MOC typically presents at early stage but demonstrates intrinsic chemoresistance; treatment of advanced-stage and relapsed disease is therefore challenging. We harness a large retrospective MOC cohort to identify factors associated with recurrence risk and survival. A total of 151 MOC patients were included. The 5 year disease-specific survival (DSS) was 84.5%. Risk of subsequent recurrence after a disease-free period of 2 and 5 years was low (8.3% and 5.6% over the next 10 years). The majority of cases were FIGO stage I (35.6% IA, 43.0% IC). Multivariable analysis identified stage and pathological grade as independently associated with DSS (<i>p</i> < 0.001 and <i>p</i> < 0.001). Grade 1 stage I patients represented the majority of cases (53.0%) and demonstrated exceptional survival (10 year DSS 95.3%); survival was comparable between grade I stage IA and stage IC patients, and between grade I stage IC patients who did and did not receive adjuvant chemotherapy. At 5 years following diagnosis, the proportion of grade 1, 2 and 3 patients remaining disease free was 89.5%, 74.9% and 41.7%; the corresponding proportions for FIGO stage I, II and III/IV patients were 91.1%, 76.7% and 19.8%. Median post-relapse survival was 5.0 months. Most MOC patients present with low-grade early-stage disease and are at low risk of recurrence. New treatment options are urgently needed to improve survival following relapse, which is associated with extremely poor prognosis.Robert L. HollisLorna J. StillieSamantha HopkinsClare BartosMichael ChurchmanTzyvia RyeFiona NusseyScott FeganRachel NirsimlooGareth J. InmanC. Simon HerringtonCharlie GourleyMDPI AGarticleovarian cancermucinoussurvivalprognosisrelapseNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5839, p 5839 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ovarian cancer mucinous survival prognosis relapse Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	ovarian cancer mucinous survival prognosis relapse Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Robert L. Hollis Lorna J. Stillie Samantha Hopkins Clare Bartos Michael Churchman Tzyvia Rye Fiona Nussey Scott Fegan Rachel Nirsimloo Gareth J. Inman C. Simon Herrington Charlie Gourley Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma
description	Mucinous ovarian carcinoma (MOC) is a unique form of ovarian cancer. MOC typically presents at early stage but demonstrates intrinsic chemoresistance; treatment of advanced-stage and relapsed disease is therefore challenging. We harness a large retrospective MOC cohort to identify factors associated with recurrence risk and survival. A total of 151 MOC patients were included. The 5 year disease-specific survival (DSS) was 84.5%. Risk of subsequent recurrence after a disease-free period of 2 and 5 years was low (8.3% and 5.6% over the next 10 years). The majority of cases were FIGO stage I (35.6% IA, 43.0% IC). Multivariable analysis identified stage and pathological grade as independently associated with DSS (<i>p</i> < 0.001 and <i>p</i> < 0.001). Grade 1 stage I patients represented the majority of cases (53.0%) and demonstrated exceptional survival (10 year DSS 95.3%); survival was comparable between grade I stage IA and stage IC patients, and between grade I stage IC patients who did and did not receive adjuvant chemotherapy. At 5 years following diagnosis, the proportion of grade 1, 2 and 3 patients remaining disease free was 89.5%, 74.9% and 41.7%; the corresponding proportions for FIGO stage I, II and III/IV patients were 91.1%, 76.7% and 19.8%. Median post-relapse survival was 5.0 months. Most MOC patients present with low-grade early-stage disease and are at low risk of recurrence. New treatment options are urgently needed to improve survival following relapse, which is associated with extremely poor prognosis.
format	article
author	Robert L. Hollis Lorna J. Stillie Samantha Hopkins Clare Bartos Michael Churchman Tzyvia Rye Fiona Nussey Scott Fegan Rachel Nirsimloo Gareth J. Inman C. Simon Herrington Charlie Gourley
author_facet	Robert L. Hollis Lorna J. Stillie Samantha Hopkins Clare Bartos Michael Churchman Tzyvia Rye Fiona Nussey Scott Fegan Rachel Nirsimloo Gareth J. Inman C. Simon Herrington Charlie Gourley
author_sort	Robert L. Hollis
title	Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma
title_short	Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma
title_full	Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma
title_fullStr	Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma
title_full_unstemmed	Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma
title_sort	clinicopathological determinants of recurrence risk and survival in mucinous ovarian carcinoma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/c8786c50a23247a98138b2bae9b70e26
work_keys_str_mv	AT robertlhollis clinicopathologicaldeterminantsofrecurrenceriskandsurvivalinmucinousovariancarcinoma AT lornajstillie clinicopathologicaldeterminantsofrecurrenceriskandsurvivalinmucinousovariancarcinoma AT samanthahopkins clinicopathologicaldeterminantsofrecurrenceriskandsurvivalinmucinousovariancarcinoma AT clarebartos clinicopathologicaldeterminantsofrecurrenceriskandsurvivalinmucinousovariancarcinoma AT michaelchurchman clinicopathologicaldeterminantsofrecurrenceriskandsurvivalinmucinousovariancarcinoma AT tzyviarye clinicopathologicaldeterminantsofrecurrenceriskandsurvivalinmucinousovariancarcinoma AT fionanussey clinicopathologicaldeterminantsofrecurrenceriskandsurvivalinmucinousovariancarcinoma AT scottfegan clinicopathologicaldeterminantsofrecurrenceriskandsurvivalinmucinousovariancarcinoma AT rachelnirsimloo clinicopathologicaldeterminantsofrecurrenceriskandsurvivalinmucinousovariancarcinoma AT garethjinman clinicopathologicaldeterminantsofrecurrenceriskandsurvivalinmucinousovariancarcinoma AT csimonherrington clinicopathologicaldeterminantsofrecurrenceriskandsurvivalinmucinousovariancarcinoma AT charliegourley clinicopathologicaldeterminantsofrecurrenceriskandsurvivalinmucinousovariancarcinoma
_version_	1718412740915101696

Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma

Ejemplares similares